Anti Inflammatory News and Research

RSS

Zyflamend, herb-based therapeutic shows promise for high risk of prostate cancer

Results of a phase I clinical trial of a novel herb-based therapeutic called Zyflamend have demonstrated that the therapy is associated with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer.

22 May 2009

Tuberculosis can evade immune response

Current research suggests that Mycobacterium tuberculosis can evade the immune response. The related report by Rahman et al, "Compartmentalization of immune responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory T cells in the granulomatous lesions," appears in the June 2009 issue of The American Journal of Pathology.

22 May 2009

A new slow-release hydrogen sulfide donating molecule may hold the key to the development of new anti-inflammatory drugs

Researchers from the Peninsula Medical School in Exeter have synthesized a new molecule which releases hydrogen sulfide (H2S) - the gas that gives rotten eggs their characteristic smell and which has recently been found to be produced naturally in the body - and discovered that it could in time lead to a range of new, safer and effective anti-inflammatory drugs for human use.

20 May 2009

Vitamin D may halt lung function decline in asthma and COPD

Vitamin D may slow the progressive decline in the ability to breathe that can occur in people with asthma as a result of human airway smooth muscle (HASM) proliferation, according to researchers at the University of Pennsylvania.

20 May 2009

Resverlogix files two patents on compounds for inflammatory diseases

Resverlogix Corp. has announced today that it has made significant advancement in the Company's research and development (R&D) program for inflammatory diseases.

19 May 2009

Obese mothers, asthmatic kids

Babies born to obese mothers may have an increased risk of asthma, according to data from a new study to be presented on May 19 at the 105th International Conference of the American Thoracic Society in San Diego.

19 May 2009

Pirfenidone shows promise for idiopathic pulmonary fibrosis

A large, well-controlled, multi-national clinical trial program has demonstrated the effectiveness and safety of what may become the first FDA-approved medicine for idiopathic pulmonary fibrosis, or IPF.

17 May 2009

Ginger reduces post-chemotherapy nausea

People with cancer can reduce post-chemotherapy nausea by 40 percent by using ginger supplements, along with standard anti-vomiting drugs, before undergoing treatment, according to scientists at the University of Rochester Medical Center.

15 May 2009

Cimzia approved in U.S. for rheumatoid arthritis

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

13 May 2009

Researchers demonstrate the immunological effects of ginseng

Researchers writing in BioMed Central's open access Journal of Translational Medicine have shown that the herb, much used in traditional Chinese and other Asian medicine, does have anti-inflammatory effects.

13 May 2009

Omega-three fatty acid rich foods lower risk for eye disease

Regularly eating fish, nuts, olive oil and other foods containing omega-three fatty acids and avoiding trans fats appears to be associated with a lower risk for the eye disease age-related macular degeneration, according to two reports in the May issue of Archives of Ophthalmology.

12 May 2009

Scientific publishing giant guilty of some shonky behaviour

It has been revealed that the academic publisher Elsevier has admitted its Australian office produced six fake medical journals between 2000 and 2005.

11 May 2009

Stem cell focus for inflammatory bowel disease wound healing

Scientists at The University of Nottingham are investigating whether stem cell markers could have a role to play in speeding up wound healing in patients suffering from inflammatory bowel disease (IBD).

30 Apr 2009

New findings on COX-2 inhibitor side effects

In searching for a simple way to identify individuals with smoking-related lung injury, scientists at Weill Cornell Medical College have stumbled upon a potential explanation for why the class of pain-relievers known as COX-2 inhibitors increases the risk of heart problems among users.

29 Apr 2009

Aspirin for forty somethings could cut cancer risk

Taking aspirin in your 40s could cut the risk of cancer developing later in life, according to research published in the Lancet Oncology.

29 Apr 2009

Statins may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms

Several new studies presented at the American Urological Association's (AUA) 104th Annual Scientific Meeting suggest that the use of statins - commonly prescribed to lower cholesterol - may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms (LUTS).

26 Apr 2009

Alternative non-surgical method to treat chronic tendinosis

Researchers have found an alternative, "non-surgical" method to treat chronic tendinosis (tendinitis) of the Achilles tendon that fails conservative treatment, according to a study performed at the Feinberg School of Medicine, Northwestern University in Chicago, IL.

23 Apr 2009

NSAIDs do not prevent Alzheimer's disease or other forms of dementia

A new study shows that nonsteroidal anti-inflammatory drugs (NSAIDs), such as the pain relievers ibuprofen and naproxen, do not prevent Alzheimer's disease or other forms of dementia.

22 Apr 2009

New applications for proton pump inhibitors

In a new study, published in the May issue of Elsevier's Experimental Neurology (www.elsevier.com/locate/yexnr), scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug.

22 Apr 2009

Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies

Peregrine Pharmaceuticals, Inc. has reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS) targeting antibodies.

22 Apr 2009